Cheryl Ho, MD, FRCP(C)
Cheryl Ho, MD, FRCPC
Clinical Associate Professor
University of British Columbia
British Columbia Cancer
Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.
Barbara Melosky, MD, FRCP(C)
Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.
Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.
She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.
Randeep Sangha, MD, FRCPC
Associate Professor, University of Alberta
Medical Oncologist, Cross Cancer Institute
Director, Clinical Trials Unit, Cross Cancer Institute
Provincial Lead, Alberta Lung Cancer Program
Randeep Sangha, MD, is an Associate Professor at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada.
Dr. Sangha obtained his medical degree from the University of Alberta Faculty of Medicine, where he also completed his his residency in Internal Medicine and Medical Oncology. He then pursued a post-training research fellowship at the University of California, Davis Comprehensive Cancer Center, focusing on thoracic malignancies.
Dr. Sangha is the Director of the Clinical Trials Unit at the Cross Cancer Institute. He also has been the Provincial Lead for the Alberta Lung Cancer Program. His clinical and research interests include treatment of thoracic and hematologic malignancies, as well as developmental and molecular therapeutics.
Devin Schellenberg, MD, FRCS(C)
Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre
Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto. He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).
He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.
Leah Backhus, MD MPH FACS
Leah Backhus MD MPH FACS, trained at the University of Southern California and the University of California Los Angeles. She is Associate Professor of Cardiothoracic Surgery at Stanford University and has grant funding through the Veterans Affairs Administration and the NIH. Her research examines imaging surveillance following treatment for lung cancer. She holds several leadership roles within the Society of Thoracic Surgeons, American Association of Thoracic Surgery, and Women in Thoracic Surgery. She also serves as Chair of the Women and Lung Cancer Task Group of the National Lung Cancer Roundtable of the American Cancer Society and prior Chair of the ACGME Thoracic Residency Review Committee.
Gordon Buduhan, MD, MPH, FACS
University of British Columbia,
Dr. Buduhan joined the Division of Thoracic Surgery at Kelowna General Hospital /Interior Health in August 2021 and is currently Clinical Associate Professor of Surgery at UBC. Prior to moving to Kelowna, he was staff thoracic surgeon at Health Sciences Centre, Winnipeg, Associate Professor of Surgery and former Program Director of the Thoracic Surgery Residency Program University of Manitoba from 2013-2021.
Dr. Buduhan was born and raised in Winnipeg Manitoba. He completed undergraduate studies at University of Manitoba, and medical school at the University of Toronto. Dr. Buduhan completed general surgery residency at the University of Manitoba. He finished his thoracic surgery fellowship training at UBC.
Dr. Buduhan also obtained additional fellowship training in minimally invasive thoracic and foregut surgery at Swedish Medical Center in Seattle, Washington.
Dr. Buduhan’s clinical focus is on all aspects of thoracic oncology, minimally invasive thoracic and esophageal surgery. His research interests include clinical trials in thoracic oncology, clinical outcomes in lung and esophageal cancer, minimally invasive thoracic surgery and cost analysis.
Shaun Coughlin, MD
Department of Surgery
Dr. Coughlin went to medical school at the University of British Columbia and then completed a general surgery residency at the University of Western Ontario. During that time he also completed a masters degree in health research methodology at McMaster. Dr. Coughlin finished his thoracic surgery residency at Western. Dr. Coughlin has been practicing thoracic surgery in Victoria BC since 2015 with an interest in minimally invasive thoracic and foregut surgery.
David Gandara, MD
Professor of Medicine Emeritus
Co-Director, Center for Experimental Therapeutics in Cancer
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
David Gandara, Professor of Medicine Emeritus at the University of California, Davis. He
is the co-director of the Center for Experimental Therapeutics and Senior Advisor to the
Director at UC Davis Comprehensive Cancer Center. He was recently appointed Adjunct
Clinical Professor, Translational and Clinical Research Program at the University of
Hawaii Cancer Center and Chief Medical Officer for International Society of Liquid Biopsy
(ISLB), a non-profit organization dedicated to advancing the science and clinical
application of liquid biopsy in cancer diagnosis and therapy. He is an internationally
known clinician-scientist and lung cancer thought leader and has published over 450
peer-reviewed papers. He has led many notable research projects in lung cancer,
including early therapeutics trials through an N01-sponsored award, cooperative group
trials as past-chair of the SWOG Lung Committee and multi-institutional translational
science projects such as clinical director of the patient-derived xenograft (PDX) lung
program in collaboration with The Jackson Laboratory Cancer Center. Dr. Gandara has
been selected for many awards and honors, including the lifetime Scientific Award from
the International Association for Study of Lung Cancer (IASLC), the Team Science Award
from the Addario Lung Cancer Foundation, and the Trajectory Achievement Award from
the ISLB. He is current principal investigator for a National Cancer Institute UG1 award
to UCDCCC for cancer clinical trials, co-leader of Lung MAP, a unique NCI-sponsored
public-private partnership for new drug development in lung cancer and is founding cochair and current member of the NCI-directed Investigational Drug Steering Committee
(IDSC). Dr. Gandara is past Editor-in-Chief of the journal Clinical Lung Cancer. He served
as president of the IASLC from 2009-2011 and as treasurer from 2013-2017. He is a prior
member of the board of directors and secretary-treasurer of ASCO. In 2017, Gandara
received the Giants of Cancer Care Award in lung cancer
Jonathan Greenland, MD, FRCP(C)
Radiation Oncologist, Eastern Health
Clinical Assistant Professor of Medicine
Memorial University of Newfoundland
St. John’s, NFLD
Dr Greenland is a radiation oncologist practicing at Eastern Health in St. John’s, NL. He completed medical school at Memorial University of Newfoundland in 1995, and a residency in Radiation Oncology at the University of Western Ontario in 2000.
His practice interests include the management of thoracic and hematologic malignancies. He chairs the Eastern Health Thoracic Disease Site committee, and is leading Eastern Health’s lung cancer screening proposal. He has a strong interest in palliative care, and is also the lead for medical assistance in dying (MAiD) for the Eastern Health cancer care program. He is a past-president of the Newfoundland and Labrador medical association, and continues to serve on its Health Information Technology committee. He enjoys sailing and gardening when the weather cooperates
David Hong, MD
Professor and Deputy Chair
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Centre
I am a Professor in and Deputy Chairman of the Department of Investigational Cancer Therapeutics (A Phase I Program), Clinical Medical Director of the Clinical Translational Research Center (CTRC), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center. I was instrumental in forming one of the largest and most innovative Phase I clinical trial units in the world, with over 1,300 patients enrolled in clinical trials in FY2021 and over 400 active ongoing clinical trials. I have been Principal Investigator of over 120 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. I have published over 374 publications in peer-reviewed journals such as NEJM, Lancet Oncology, JCO, and Nature. I have been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib, larotrectinib, tesotumab vendotin, and sotorasib, the first drug to target KRAS, that have led to FDA approval. I also helped found two companies: OncoResponse and Telperian. I am an expert on c-Met , NTRK, KRAS, and adoptive cellular therapy in solid tumors, and have led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss Award at MD Anderson, Irwin Krakoff Award for Clinical Research, and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.
Andrew Hope, MD, FRCPC
Department of Radiation Oncology
University of Toronto
Dr. Hope is a Clinician Investigator within the Radiation Medicine Program at the Princess Margaret Cancer Centre and Associate Professor in the Department of Radiation Oncology, University of Toronto. His primary research goal has been to understand tthe relationship between radiation treatments and the resultant normal tissue toxicities. He specializes in treating patients with thoracic and head and neck malignancies where toxicities remain unfortunately common.
Biniam Kidane, MD, MSc, FRCSC
Thoracic & Foregut Surgeon, Section of Thoracic Surgery
Associate Professor of Surgery, College of Medicine, University of Manitoba
Medical Director, Wilf Taillieu Thoracic Clinic & Endoscopy Unit
Research Director, Thoracic Surgery and Surgical Peri-Operative Research Team (SPORT)
Dr. Kidane is a thoracic and foregut surgeon with a special interest in minimally invasive and endoscopic approaches to benign and malignant thoracic/foregut disease. He was recruited to Manitoba to establish an advanced diagnostic and therapeutic endoscopy program for thoracic diseases. Dr. Kidane has a research interest in peri-operative care and a translational research program in the relationship between intra-operative inflammation and short- and long-term oncological outcomes. His major interest is in lung-protective ventilation during thoracic surgery. He also has a research interest in health services and outcomes research as it relates to esophageal and lung cancer.
Geoffrey Liu, MD, FRCPC, FISPE
Professor of Medicine, Medical Biophysics, Epidemiology
Institute of Medical Science
University of Toronto & Dalla Lana School of Public Health
Dr. Geoffrey Liu , MD FRCPC FISPE is the Alan B. Brown Chair in Molecular Genomics, a thoracic medical oncologist, and Professor of Medicine, Medical Biophysics, Epidemiology, and at the Institute of Medical Science at the University of Toronto and the Dalla Lana School of Public Health. He is a Senior Scientist at the Ontario Cancer Institute and runs the Applied Molecular Pharmacogenomic Profiling and Epidemiological Laboratory (AMPPEL). He is a Fellow of the International Society for Pharmacoepidemiology, where he is on the committee for developing real world evidence guidelines for the society. His research interests are in clinical, germline, and somatic pharmacogenomics, secondary resistance patterns in targeted agent therapy, utilizing primary derived xenograft and organdies to identify biomarkers of susceptibility and resistance to targeted agents, routine collection of patient-reported and health utility data, and regulatory grade real world evidence methodology.
Raymond Mak, MD
Associate Professor of Radiation Oncology
Harvard Medical School
Director of Clinical Innovation
Department of Radiation Oncology & the Artificial Intelligence in Medicine Program
Brigham and Women’s Hospital/Dana-Farber Cancer Institute
Raymond Mak MD, is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation in the Department of Radiation Oncology and the Artificial Intelligence in Medicine Program at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. Dr. Mak has clinical expertise in thoracic malignancies, stereotactic body radiation therapy and novel radiation therapy techniques, including leading the development of MR-guided radiation therapy and adaptive therapy programs. His research focuses on developing imaging biomarkers to predict radiation therapy response in lung cancer patients and applying artificial intelligence (AI) techniques to automate radiation therapy planning and improve decision support. He is leading clinical testing and implementation of AI throughout the patient care spectrum of radiation oncology.
Vishal Navani, MA (Oxon), MBBS (Lon), MRCP (UK), FRACP
Tom Baker Cancer Centre
Dr. Navani is a staff medical oncologist at the Tom Baker Cancer Centre. He previously graduated from Oxford and Imperial College London. He holds both Membership of the Royal College of Physicians of the United Kingdom and Fellowship of the Royal Australasian College of Physicians. His academic focus includes the interrogation of large real world datasets spanning tumour streams in order to generate practical insights that can be used in the clinic. He is a clinical director at Glans Look, Canada’s largest lung cancer database. His award-winning real-world research has been published extensively in high impact journals. He plays a lead role in academic endeavours at the University of Calgary such as the Precision Oncology and Experimental Therapeutics programme and has contributed as a clinical expert to CADTH national drug reimbursement decisions. He provides clinical development advice to a number of life science companies.
Masahide Oki, MD, PhD, FCCP
Nagoya Medical Center
Dr. Oki has been a chief of Department of Respiratory Medicine at Nagoya Medical Center since 2009. His main research interest is interventional pulmonology, and he has published a lot of papers in the field. He received Shigeto Ikeda Award from the Japan Society of Respiratory Endoscopy in 2014, and the WABIP-Dumon Award from the World Association for Bronchology and Interventional Pulmonology in 2016.
David Palma, MD, PhD, FRCPC
Professor, Western University
Radiation Oncologist, London Health Sciences Centre
Dr. David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Canada. He holds an MD from the University of Western Ontario, a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He has led several international randomized trials in radiation oncology, and he is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group. He is the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.
Nazgol Seyednejad MD, FRCSC
Surrey Memorial Hospital
Fraser Health Authority
Dr. Seyednejad BMLSc, MD, FRCSC (General and Thoracic Surgery) is a Thoracic Surgeon at Surrey Memorial Hospital and Fraser Health Authority. After completion of medical school and General Surgery residency at the University of British Columbia, Dr. Seyednejad pursued subspecialty training in Thoracic Surgery at the University of Ottawa. Her main interest is in the management and treatment of esophageal and lung malignancies. She has been the author and co-author of various peer reviewed publications focused on General and Thoracic oncology.
Stephanie Snow, MD, FRCPC
Medical Oncologist, QEII Health Sciences Centre
Associate Professor, Dalhousie University
President, Lung Cancer Canada
Dr. Stephanie Snow is a staff Medical Oncologist at the QEII hospital in Halifax, Nova Scotia and is currently an Associate Professor at in the Faculty of Medicine at Dalhousie. After pursuing undergraduate training at McGill, she completed training at Dalhousie. She treats thoracic and GI malignancies. She has a strong interest in Medical Education and is Vice Chair of the Royal College Medical Oncology Examination Board. She also has a keen interest in patient advocacy, serving as the current President of Lung Cancer Canada, and sitting on the medical advisory committees of several other patient advocacy groups in colorectal and gastric cancer.
Dawn Stacey RN, PhD, CON(C), FCAHS, FAAN, FCAN
University Research Chair, Knowledge Translation to Patients
Distinguished University Professor
School of Nursing, Faculty of Health Sciences
University of Ottawa
Dr. Stacey is a Distinguished University Professor who holds the University Research Chair in Knowledge Translation to Patients. As a senior scientist at the Ottawa Hospital Research Institute, she is the scientific director of the patient decision aids research group. She has expertise in decision sciences and implementation science. Her research is focused on developing, evaluating, and implementing interventions to support patients to be active partners in making healthcare decisions. She leads interdisciplinary research teams to conduct original research with practical application for healthcare services, patients, families, healthcare professionals and students.